Structure–Activity Relationship (SAR) Studies of Novel Monovalent AR/AR-V7 Dual Degraders with Potent Efficacy against Advanced Prostate Cancer
- 21 March 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (7) , 5567-5590
Abstract
Androgen receptor (AR) has been extensively established as a potential therapeutic target for nearly all stages of prostate cancer (PCa). However, acquired resistance to AR-targeted drugs inevitably develops and severely limits their clinical efficacy. Particularly, there currently exists no efficient treatment for patients expressing the constitutively active AR splice variants, such as AR-V7. Herein, we report the structure-activity relationship studies of 55 N-heterocycle-substituted hydantoins, which identified the structural motifs required for AR/AR-V7 degradation. Among them, the most potent compound 27c exhibited selective AR/AR-V7 degradation over other hormone receptors and excellent antiproliferative activities in LNCaP and 22RV1 cells. RNA sequence analysis confirmed that 27c effectively suppressed transcriptional activity of the AR signaling pathway. Importantly, 27c demonstrated potent antitumor efficacy in an enzalutamide-resistant 22RV1 xenograft model. These results highlight the potential of 27c as a promising dual AR/AR-V7 degrader for overcoming drug resistance in advanced PCa expressing AR splice variants.Keywords
Funding Information
- Natural Science Foundation of Jiangsu Province (BK20210423)
- National Natural Science Foundation of China (82103978)
This publication has 37 references indexed in Scilit:
- Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancerEuropean Journal of Medicinal Chemistry, 2023
- Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate CancerJournal of Medicinal Chemistry, 2021
- Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate CancerJournal of Medicinal Chemistry, 2021
- Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate CancerJournal of Medicinal Chemistry, 2020
- Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical ApplicationsJournal of Medicinal Chemistry, 2020
- Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants MeetingEuropean Urology, 2018
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerJAMA Oncology, 2016
- Androgen receptor (AR) aberrations in castration-resistant prostate cancerMolecular and Cellular Endocrinology, 2012
- New Therapies for Castration-Resistant Prostate Cancer: Efficacy and SafetyEuropean Urology, 2011
- Androgen receptor action in hormone‐dependent and recurrent prostate cancerJournal of Cellular Biochemistry, 2006